Close
Smartlab Europe
Achema middle east

Press Releases

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Deutsche Bank Global Health Care Conference on Wednesday, May 6, 2015, in Boston. Giovanni Caforio, chief operating officer and CEO-designate, will answer questions about the company at 10:40...

Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts

INDIANAPOLIS, May 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts – a strategic location that will help attract top scientists and bioengineers,...

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas. Doug Manion, head, Specialty Development, will make a formal presentation about the...

Lilly Declares Second-Quarter 2015 Dividend

INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2015 of $0.50 per share on outstanding common stock. The...

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

Application includes CheckMate -066, a clinical trial of Opdivo vs. dacarbazine chemotherapy in patients who had not received prior therapy. CheckMate -066 marked the first time that a PD-1 immune checkpoint inhibitor demonstrated survival in a...

Bristol-Myers Squibb Prices €1.15 Billion of Senior Notes

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell €1.15 billion of senior unsecured notes: €575,000,000 in aggregate principal amount of 1.000% notes due 2025 and €575,000,000 in aggregate principal amount of 1.750% notes...

Bristol-Myers Squibb Reports First Quarter Financial Results

Reports Revenues of $4.0 Billion in the First Quarter Posts First Quarter GAAP and Non-GAAP EPS of $0.71 Achieves Key Data and Regulatory Milestones Across Portfolio Completes Strategic Transactions in Immuno-Oncology and Cardiovascular,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »